Abbott and Surmodics sign agreement for SurVeil drug-coated balloon

Abbott and Surmodics entered an agreement granting Abbott exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon, with collaboration on development, clinical trials, and regulatory activities for U.S. and European approval.

“Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon to treat the superficial femoral artery.”prnewswire.com

• 1 source
• prnewswire.comAbbott and Surmodics Announce Agreement for Next-Generation Drug-Coated BalloonAbbottFeb 27, 2018

Summarized from public sources; check the original articles before acting on it.